Moleculin Biotech Nears First Unblinding Milestone in Pivotal Phase 3 AML Trial
I'm PortAI, I can summarize articles.
Moleculin Biotech Inc. is nearing the first unblinding milestone in its pivotal Phase 3 AML trial. As of November 4, 2025, 60% of the targeted 45 subjects have consented to participate. The company expects to complete treatment of these patients in Q1 2026, with initial unblinded data to follow. The trial spans five countries, with further unblinding anticipated in the first half of 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments